I honestly don't know. I am not implying that. The blood markers are interesting but not proof Aethlon's product is in use. I'd like to believe there is some news before the shareholder meeting. But until they state it, it is not so. I'd like to believe the Accesswire press release that mentioned Lilly got it wrong and it's really something with Abbott. However it may certainly be the case that Accesswire was flat wrong and there is nothing with Abbott. The good news regardless is that blood markers are viable as a method for learning more.